Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 631 to 632 of 632 total matches.
Inavolisib (Itovebi) for Locally Advanced or Metastatic Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
of the
phosphatidylinositol 3-kinase (PI3K) pathway can lead
to uncontrolled cellular growth and tumorigenesis.1
Inavolisib ...
Inavolisib (Itovebi – Genentech), an oral kinase
inhibitor, has been approved by the FDA for use in
combination with palbociclib and fulvestrant for
treatment of endocrine-resistant, PIK3CA-mutated,
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer. This is the first
approval for Itovebi; palbociclib and fulvestrant have
been available for years for treatment of HR-positive,
HER2-negative breast cancer.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):e186-7 doi:10.58347/tml.2024.1715f | Show Introduction Hide Introduction
Table 3: Some Drug Interactions with DAAs for HCV Infection (online only)
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024 (Issue 1714)
; OATP = organic anion transporting polypeptide.
1. The University of Liverpool maintains ...
View Table 3: Some Drug Interactions with DAAs for HCV Infection
Med Lett Drugs Ther. 2024 Oct 28;66(1714):e175 doi:10.58347/tml.2024.1714f | Show Introduction Hide Introduction